Lb Pharmaceuticals (LBRX) Accumulated Depreciation (2024 - 2026)

Lb Pharmaceuticals' Accumulated Depreciation history runs 3 years deep, the most recent figure standing at $502000.0 for Q1 2026.

• On a quarterly basis, Accumulated Depreciation changed N/A year-over-year to $502000.0 in Q1 2026; TTM through Mar 2026 was $502000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $420000.0, up 315.84% from the prior year.
• Accumulated Depreciation rose to $502000.0 in Q1 2026 per LBRX's latest filing, from $420000.0 in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $502000.0 in Q1 2026 and bottomed at $101000.0 in Q4 2024.
• The 3-year median for Accumulated Depreciation is $378500.0 (2025), against an average of $340000.0.
• Biggest YoY gain for Accumulated Depreciation was 315.84% in 2025; the steepest drop was 315.84% in 2025.
• Year by year, Accumulated Depreciation stood at $101000.0 in 2024, then jumped by 315.84% to $420000.0 in 2025, then gained by 19.52% to $502000.0 in 2026.
• Per Business Quant, the three latest LBRX Accumulated Depreciation figures stand at $502000.0 (Q1 2026), $420000.0 (Q4 2025), and $337000.0 (Q3 2025).